Cipla, Guojian launch first biosimilar Enbrel in India
This article was originally published in Scrip
Executive Summary
Cipla has launched the first cut-price etanercept, a biosimilar version of Amgen's Enbrel, in India under an alliance with Shanghai CP Guojian Pharmaceutical, marking the Indian generic company's much anticipated entry into the biologics space.
You may also be interested in...
Cipla Primes Biosimilars Play Via South African Beachhead
South Africa’s first biotech manufacturing facility is being set up by India's Cipla which hopes its strategy of "one global product standard at affordable pricing" could transform the biosimilars market. Some years ago, Cipla revolutionized treatment for HIV/AIDS with its less than a dollar a day treatment, though some analysts claim that it's still very early days to factor any disruptive impact that the firm could potentially have in the complex biosimilars segment.
Cipla Primes Biosimilars Play Via South African Beachhead
South Africa’s first biotech manufacturing facility is being set up by India's Cipla which hopes its strategy of "one global product standard at affordable pricing" could transform the biosimilars market. Some years ago, Cipla revolutionized treatment for HIV/AIDS with its less than a dollar a day treatment, though some analysts claim that it's still very early days to factor any disruptive impact that the firm could potentially have in the complex biosimilars segment.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.